Jeil Pharmaceutical's Overactive Bladder Treatment 'Beoba Tablets' Approved by MFDS

Jeil Pharmaceutical Headquarters View. [Photo by Jeil Pharmaceutical]

[Asia Economy Reporter Lee Gwan-joo] Jeil Pharmaceutical announced on the 1st that it has received approval from the Ministry of Food and Drug Safety for the new drug for overactive bladder treatment, 'Beoba Tablet 50 milligrams' (generic name: vibegron).

Beoba Tablet is a new drug for overactive bladder treatment developed by Japan's Kyorin Pharmaceutical. It selectively acts on the bladder's beta-3 (β-3) adrenergic receptors to relax the detrusor muscle of the bladder, treating ▲frequency ▲urgency (a strong need to urinate that is difficult to hold) ▲urgency urinary incontinence (involuntary muscle contractions causing urine leakage due to a strong urge to urinate).

In particular, compared to existing anticholinergic drugs, it is expected to have excellent effects in treating overactive bladder as well as improvements in uncomfortable symptoms such as dry mouth, indigestion, and decreased tearing that may occur with long-term use.

Previously, Jeil Pharmaceutical conducted a Phase 1 clinical trial for in-house production purposes. A bridging Phase 3 clinical trial of Beoba Tablet was conducted on 210 overactive bladder patients at 20 domestic institutions including Seoul Asan Medical Center, demonstrating significant improvement in urgency and urgency urinary incontinence compared to placebo, thereby proving safety and efficacy.

Jeil Pharmaceutical plans to supply Beoba Tablet to the domestic market next year. A Jeil Pharmaceutical official said, “The launch of Beoba Tablet will provide an additional treatment option for patients with overactive bladder syndrome,” adding, “We hope it will help improve the quality of life for medical professionals and patients with unmet needs.”

This content was produced with the assistance of AI translation services.